These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 9570424)

  • 1. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
    Noll G; Lüscher TF
    Cardiology; 1998; 89 Suppl 1():10-5. PubMed ID: 9570424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic profile of Ro 40-5967 in conscious rats: comparison with diltiazem, verapamil, and amlodipine.
    Véniant M; Clozel JP; Hess P; Wolfgang R
    J Cardiovasc Pharmacol; 1991; 18 Suppl 10():S55-8. PubMed ID: 1725005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human vascular to cardiac tissue selectivity of L- and T-type calcium channel antagonists.
    Sarsero D; Fujiwara T; Molenaar P; Angus JA
    Br J Pharmacol; 1998 Sep; 125(1):109-19. PubMed ID: 9776350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists.
    Davies GJ; Tzivoni D; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):34C-39C. PubMed ID: 9286852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mibefradil, a pharmacologically distinct calcium antagonist.
    Ernst ME; Kelly MW
    Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mibefradil: a new class of calcium-channel antagonists.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.
    Brogden RN; Markham A
    Drugs; 1997 Nov; 54(5):774-93. PubMed ID: 9360062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of mibefradil and other calcium antagonists on resistance arteries of different end organs.
    van der Lee R; Pfaffendorf M; van Zwieten PA
    Fundam Clin Pharmacol; 1999; 13(2):198-203. PubMed ID: 10226764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term hemodynamic effects of mibefradil in dogs with chronic heart failure: comparison with diltiazem.
    Shimoyama H; Sabbah HN; Tanimura M; Borzak S; Goldstein S
    J Pharmacol Exp Ther; 1998 May; 285(2):746-52. PubMed ID: 9580622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.
    Massie BM; Lacourcière Y; Viskoper R; Woittiez A; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):27C-33C. PubMed ID: 9286851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T- and L-type Ca2+-channel antagonists reduce contractility in guinea pig cardiac myocytes.
    Hoischen S; Brixius K; Schwinger RH
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):323-30. PubMed ID: 9700997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the calcium channel blockers, diltiazem and Ro 40-5967, on systemic haemodynamics and plasma noradrenaline levels in conscious dogs with pacing-induced heart failure.
    Su J; Renaud N; Carayon A; Crozatier B; Hittinger L
    Br J Pharmacol; 1994 Oct; 113(2):395-402. PubMed ID: 7834190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular T-type calcium channels: physiological and pharmacological significance.
    Triggle DJ
    J Hypertens Suppl; 1997 Dec; 15(5):S9-15. PubMed ID: 9481611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of mibefradil, a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation.
    Billman GE; Hamlin RL
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1517-26. PubMed ID: 8667218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential properties of mibefradil in hypertension and angina.
    Kobrin I
    J Hypertens Suppl; 1997 Dec; 15(5):S33-40. PubMed ID: 9481614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent vasodilatory with minor cardiodepressant actions of mibefradil in human cardiac tissue.
    Brixius K; Mohr V; Müller-Ehmsen J; Hoischen S; Münch G; Schwinger RH
    Br J Pharmacol; 1998 Sep; 125(1):41-8. PubMed ID: 9776342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of mibefradil, a novel calcium channel blocking agent with T-type activity, in acute experimental myocardial ischemia: maintenance of ventricular fibrillation threshold without inotropic compromise.
    Muller CA; Opie LH; McCarthy J; Hofmann D; Pineda CA; Peisach M
    J Am Coll Cardiol; 1998 Jul; 32(1):268-74. PubMed ID: 9669280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ro 40-5967, a novel calcium channel antagonist, protects against ventricular fibrillation.
    Billman GE
    Eur J Pharmacol; 1992 Dec; 229(2-3):179-87. PubMed ID: 1490522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diversity of calcium antagonists.
    Pitt B
    Clin Ther; 1997; 19 Suppl A():3-17. PubMed ID: 9385501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967).
    Bezprozvanny I; Tsien RW
    Mol Pharmacol; 1995 Sep; 48(3):540-9. PubMed ID: 7565636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.